

The effect of oral N-acetylcysteine on serum creatinine in chronic kidney diseases patients under CABG surgery

Mehdi Dehghani Firoozabadi¹, Ahmad Ebadi^{2*}

¹Assistant Professor of Cardiac Anesthesiology MD, Department of anesthesiology, Shahid Sadoughi University of Medical Sciences-Yazd, Iran

²Associate Professor of Cardiac Anesthesiology MD, Department of Cardiac Anesthesiology, Golestan Hospital, and Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding Author E-mail: Ebadi1959@ajums.ac.ir

Contact us:

Ahvaz Jundishapur University of Medical Sciences, Golestan Hospital Cardiovascular Anesthesia, Ahvaz, Khuzestan, IRAN, Dr Ahmad Ebadi Telephone: +989161110099 Work Fax: +986113743017

Abstract: Background: Many researches show risk factors of cardiac disease in individuals suffering from chronic kidney disease (CKD). In CKD patients who are candid CABG, there are great concerns about acute kidney injury. Increase in serum Creatinine is associated with increase in morbidity and mortality in CABG patients. Therefore, purpose of this study is investigating serum creatinine variation and GFR after oral NAC injection in CKD patients who are candid for CABG. **Material and Method:** 50 patients candid for CABG were selected in blind design randomized, clinical trial in Golstan and Imam' hospitals in Ahvaz during 2010-2011. All patients had nephropathy type 2 based on kidney fund classification and had diagnostic criteria for chronic kidney diseases or it lasts for three months (GFR<90, Cr>1.5). Intervention group received 600mg oral NAC twice a day from one day before surgery to 5 days after surgery through esophagus catheter and control group received distilled water with same amount and volume. Finally the serum creatinine, GFR and some other factors were measured. **Results:** there is a significant difference in serum creatinine (P=0.002), GFR (P=0.002) and BUN (P=0.034) between control and intervention groups after 5days. **Conclusion:** Results of this study and its comparison with other studies showed great disagreement about effect of NAC on serum creatinine but considering lack of side effects or severe changes in serum creatinine in NAC receiving patients, it can be used as a safe drug.

[Mehdi Dehghani Firoozabadi, Ahmad Ebadi. **The effect of oral N-acetylcysteine on serum creatinine in chronic kidney diseases patients under CABG surgery.** *Life Sci J* 2014;11(4s):138-143]. (ISSN:1097-8135). <http://www.lifesciencesite.com>. 19

Key words: N-acetylcysteine, serum creatinine, GFR, chronic kidney diseases(CKD), CABG

Introduction

Cardiac and kidney failure diseases are increasing everyday [1] and evidences show that failure in kidney function leads to cardiac failure and vice versa [2]. Many researches show risk factors of cardiac disease in individuals suffering from chronic kidney disease(CKD) [3-4] and it is observed that kidney diseases increase cardiovascular diseases, mortalities and morbidities [5] such that we can say patients suffering from CKD will die as a result of cardiovascular diseases not advanced kidney failures [6] because rate of stroke in CKD patients is high and can lead to death related to cardiovascular diseases [7] and it is estimated that 13% of CKD patients suffer from myocardial stroke [8-9]. In CKD patients who are candid for coronary artery bypass grafting (CABG), there are great concerns about acute Kidney failure and rate of acute kidney injury (AKI) after cardiac surgery varies from 1-3% dependent on patients' characteristics [10]. Various studies have reported that increase in serum Creatinine is associated with increase in morbidity and mortality in

CABG patients under pump [11] and slight increase in serum Creatinine leads to cardiovascular injuries and stroke [12]. Reports indicated that increase in serum creatinine is seen in 20-40% of patients hospitalized because of cardiac failure[13-15]. Creatinine is used for estimating glomerular filtration rate (GFR) [16] and one of risk factors in cardiovascular diseases in CKD patients is reducing GFR after increasing serum creatinine [17]. Results of researchers show that there is difference about dependence or independence of serum creatinine variations relative to GFR [18-21] because serum creatinine is influenced by factors like age, gender, race and body mass index and it is necessary to consider these important factors to understand relationship between increasing Creatinine and reducing GFR with accurate information and development of cardiovascular diseases [22]. Reports indicate that increase in serum creatinine increases morbidity, mortality, hospitalization, return to hospital and costs [23-26]. N-acetylcysteine (NAC) is studied for preventing kidney injury and in this study

serum creatinine variation was controlled for evaluating GFR [27]. It is necessary to mention that one of important mechanisms for kidney injury is oxidative stress [28] and NAC is a sulfhydryl-containing compound which has strong anti-oxidative features [29]. NAC is suitable for cardiac function improvement after myocardial stroke [30]. Studies have stated that NAC can reduce serum creatinine [31] but instead of these studies NAC has a contrasted history about preventing kidney injuries [32-33] and even reduction in serum creatinine after NAC injection was debated by researchers [34-35]. Therefore, purpose of this study is investigating serum creatinine variation and GFR after oral NAC injection in CKD patients who are candid for CABG.

Methods:

After approval of ethic committee in by Ahvaz Jundishapur University of Medical Sciences and consent form signed by participants, 50 patients candid for CABG were selected in blind design randomized, clinical trial in Golstan and Imam' hospitals in Ahvaz during 2010-2011. All patients had nephropathy type 2 based on kidney fund classification and had diagnostic criteria for chronic kidney diseases or it lasts for three months (GFR<90, Cr>1.5). Patients who had dialysis before surgery or emergency operation or kidney implant or received contrast drug one week before study were excluded from the study. Other patients were assigned randomly to groups receiving NAC and placebo. Intervention group received 600mg oral NAC twice a day from one day before surgery to 5 days after surgery through esophagus catheter and control group received distilled water with same amount and volume. Patients received 0.1mg/kg intramuscular morphine and 25mg promethazine. They consumed their heart drug until the day before surgery (except ACE-I). Patients received intravenous prophylactic antibiotic Cephazoline 1.5g in each 8 hours until 24 hours. Analgesic drugs initiated with thiopental 2-3 mg/kg and phentanal (3-5 mg/kg) and Atrachorim (0.5mg/kg) and midazolam (0.1mg/kg) for EKG and CVP and patients were monitored. Circular membrane oxygenator was used. Prime solution was given with 1 liter normo-smolar ringer, 500cc glucose and one vial bicarbonate and 100cc manitol were given before surgery. Flow rate was determined such that average blood pressure was 60-80 mmHg. In connecting to CPB, before recovery and 2 hours after surgery systolic blood pressure, diastole, heart rate, CVP, PaO₂, artery pH and SaO₂ were measured and recorded. Blood pressure measurement was done invasively. CVP was evaluated with pressures. Blood gases including PaO₂, pH and Sao₂ were measured. Patients were measured for connecting membrane.

When systolic blood pressure was lower than 90mmHg, Intrope was injected with 0.1-0.01ug/kg/min. additional ringer was used to maintain stable fluid level. Hemodilation was done to keep 7g/dl Hg. Myocardial monitoring with forward and backward Cardioplagy was done with cold blood. After surgery all contents were returned to patients. After surgery patients was transferred to ICU to sedate and prophel was injected for re-warming. In the case of homodynamic stability and pain control patient was removed from mechanical ventilation. Hemodynamic management in patients includes keeping MAP>65 with crystalloid and Cloido-infusion Dopamine and epinephrine were injected, when necessary.

Results:

Results of study showed that primary characteristic of patients in study and their histories in both control and intervention group had not significant differences with each other (table 1). Data analysis indicated that cardiac EF of both groups had no significant differences (P=0.164). Mean total bypass time was 72.72+/-16.35 for control group and 88.40+/-12.88 for intervention group. This time had significant differences between both groups (P=0.003). from BUN concentration comparison we can show that using NAC will significantly decrease BUN in CABG surgery (P=0.034). This reduction in concentration in intervention group is higher than control group. Comparing Na, K, HCO₃ concentration between both control and intervention groups in different times showed insignificant differences between both groups and we can conclude that using NAC has not significant effect on Na, K and HCO₃ concentration in CABG patients. Based on Freidman analysis there was a significant statistical differences in creatinine variation one day before surgery to 5 days after surgery in control group such that mean creatinine was increased from 1.60 mg/dl to 1.90 mg/dl in day 0. Based on this test, there was a significant difference in creatinine variation form one day before surgery and 5 days after surgery such that its mean reduced from 1.80 mg/dl to 1.40 mg/dl. Based on Mann-Whitney test there is a significant difference between creatinine in day 5 between control and intervention groups (P=0.002). Mean creatinine was increased in control group but decreased in intervention group (figure 1). Based on this test, there is a significant difference between groups from day 5. Based on Friedman test, there is a significant statistical difference between GFR from one day before surgery to 5 days after surgery in control group such that mean GFR was reduced from 47.03 in day 0 to 41.62 ml in minutes. Based on this test there was a significant statistical

difference between GFR from day 1 before surgery to 5 days after surgery in intervention group such that median GFR increased from 40.70 in day 0 to 51.90 ml in minutes (figure 2).

Discussion

CKD patients cannot participate in clinical trials because there are great concerns about side effects of drugs and methods but it is clear that there is a need for more studies to increase life quality of these patients. As results of this study show, changes in serum creatinine has increased in control group but

decreased in intervention group and caused GFR difference between both groups such that mean GFR increased in intervention group but decreased in control group. Adabag (36) et.al, by studying effect of oral NAC on AKI prevention after cardiac surgery, had reported that serum creatinine in NAC group has increases 0.45+0.7mg/dl but 0.55+0.9mg/dl in control group, but this difference in not significant and serum creatinine increase in NAC group in this study was lower than control group(P=0.53). Staniloae (37) et.al in a study on NAC effects on preventing nephropathy caused by contrast

Table 1. Preoperative characteristics(No Statistically Significant Difference) COPD: chronic obstructive pulmonary

Variable	Control group (n = 25)	Nacetylcysteine group (n = 25)	P Value
Age	63.28+8.21	62.041+8.62	0.651
Male sex	20(80.0)	22(88.0)	0.702
Weight	75.1614.04+	70.80+12.52	0.317
Stature	165.44+7.49	164.44+9.09	0.846
Hypertension	15(60.0)	13(52.0)	0.776
Diabetes	11 (44.0)	10(40.0)	1.000
Hyperlipidemia	14(56.0)	17(68.0)	0.561
COPD	1(4.0)	5(20.0)	0.189
Vascular disease	3(12.0)	0	0.235
Stroke	3(12.0)	0	0.235
MI	11(44.0)	15 (60.0)	0.396

disease ,MI: myocardial infarction




Figure 1




Figure 2

In angiography patients with kidney failures showed that serum creatinine was increased in 4.2% intervention group patients while in control group 6.5% patients had increase in serum creatinine but this was not significant ($P=0.38$). But like our study increase in serum creatinine was lower in intervention group. Following other studies we reach other results such that Wesner (38) et.al in their study "effect of oral NAC injection before surgery on postoperative blood lose, indicated that mean serum creatinine variances in intervention and control groups was not significantly difference in recharge relative to base line($p=0.769$) but in their studies, mean serum creatinine variances in intervention group increased $0.001+0.211\text{mg/dl}$ but $0.004+0.175\text{mg/dl}$ in control group which in contrast with our study, in their study NAC increases serum creatinine which was not significant. In other study Burns(39) et.al studied effect of perioperative NAC drug effect on kidney failure in high risk CABG patients and showed that in 29.7% of NAC receiving group serum creatinine was increased but in control group 29% had increase which was not significant($p=0.89$). Webb(40) et.al, by studying effect of NAC on preventing nephropathy caused by contrast in cardiac catheterization, showed that in NAC group 7.3% patients had increase in serum creatinine while this increase occurred in 5.7% patients in control group and in their study, NAC has increased serum creatinine but was not statistically significant($p=0.57$) and contrasted with our results. It is necessary to mention that in this study we have investigated effect of NAC on other factors like HCO_3^- , K, Na and BUN which had significant difference in BUN. Therefore, it is suggested that

other studies investigate creatinine variation and other factors like BUN.

Conclusion:

Results of this study and its comparison with other studies showed great disagreement about effect of NAC on serum creatinine and certain decision-making is not possible, but it is suitable considering lack of side effects or severe changes in serum creatinine in NAC receiving patients.

Acknowledgement: Authors acknowledge the support by Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Corresponding Author:

Ahmad Ebadi

Associate Professor of Cardiac Anesthesiology MD, Department of Cardiac Anesthesiology, Golestan Hospital, and Pain Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

E-mail: Ebadi1959@ajums.ac.ir

References

1. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. *Eur Heart J*. 2012;33:2135–42
2. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. *Circ Res* 2012,111: 1470–1483
3. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J: The prevalence of nontraditional risk factors for coronary heart

- disease in patients with chronic kidney disease. *Ann Intern Med*, 2004; 140: 9–17
4. Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS: Cardiovascular disease risk factors in chronic renal insufficiency. *Clin Nephrol*, 2002; 57: 327–335
 5. Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol* 2006; 17: 2034–2047
 6. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Hypertension*. 2003;42:1050–1065
 7. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. *Eur Heart J* 2006; 27: 1245–1250
 8. Bansal N. Clinically silent myocardial infarctions in the CKD community. *Nephrology Dialysis Transplantation*, 2012; 27:9, 3387-3391
 9. Rizk DV, Gutierrez O, Levitan EB et al. Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease. *Nephrol Dial Transplant* 2011. [Epub ahead of print December 13]
 10. Mangan, Cm Diamondstone L.S Ramsay JC, et al: multicenter study of preoperative Ischemia Research Group Renal dysfunction after my condiel revascularisatives is at el Ann mten Med 1998: 128:194-203
 11. Lee SY, Choi JB, Lee MK. Changes of Renal Function and Treatment after CABG in Patients with Elevated Serum Creatinine. *Korean J Thorac Cardiovasc Surg*. 2005;38(2):146-151.
 12. Hoke M, Amighi J, Mlekusch W, Schlager O, Exner M, Sabeti S, Dick P. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. *Stroke*. 2010;41:674-679.
 13. Butler J, Chirovsky D, Phatak H, McNeill A, Cody R. Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. *Circ Heart Fail* 2010;3:726–745.
 14. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. *Eur J Heart Fail* 2008;10:188–195.
 15. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM. The prognostic importance of different definitions of worsening renal function in congestive heart failure. *J Card Fail* 2002;8:136–141
 16. Schöttker B, Herder C, Müller H, Brenner H, Rothenbacher D. Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes. *Diabetes Care* 2012 ; 35 : 879-886
 17. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol*. 2004;15(5):1307–1315.
 18. Izzedine H, Guerin V, Launay-Vacher V, Bernad M, Deray G: Effect of N-acetylcysteine on serum creatinine level. *Nephrol Dial Transplant*, 2001: 16: 1514–1515
 19. Hasse M, Hasse-Fielitz A, Ratnaike S, Reade MC, Bagshaw SM, Morgera S, Dragun D, Bellomo R: N-acetylcysteine does not artifactually lower plasma creatinine concentration. *Nephrol Dial Transplant*, 2008: 23: 1581–1587
 20. Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. *Am J Kidney Dis* , 2002: 40: 221–225
 21. Mainra R, Gallo K, Moist L: Effect of N-acetylcysteine on renal function in patients with chronic kidney disease. *Nephrology*, 2007: 12: 510–513
 22. Dimopoulos K, Diller GP, Koltsida E, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. *Circulation*. 2008;117:2320–2328
 23. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. *Am Heart J* 2004;147:331–338.
 24. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. *J Am Coll Cardiol* 2006;47:1987–1996.

25. Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ; COACH investigators. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). *Eur J Heart Fail* 2009;11:847–854.
26. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. *J Card Fail* 2007;13:599–608.
27. Hoffmann U, Fischereder M, Kruger B, Drobnick W, Kramer BK: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. *J Am Soc Nephrol*, 2004; 15: 407–410
28. starkopf j zilmer k , vihalemmt , et al: time course of oxidative stress during open hearts surgery. *Scand j thoracic cardiovascular surgery* 1995; 29:181-186
29. Briguori C, Marenzi G. Contrast-induced nephropathy: pharmacological prophylaxis. *Kidney Int Suppl*. 2006; 100:S30-38
30. Rosato E, Cianci R, Barbano B, Menghi G, Gigante A, Rossi C, et al. N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis. *Acta Phar- macol Sin*. 2009;30:1283–8
31. Rehman T, Fought J, Solomon R. N-acetylcysteine effect on serum creatinine and cystatin
32. C levels in CKD patients. *Clin J Am Soc Nephrol* 2008;3:1610–1614
33. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. *BMC Med*. 2004;2:38-49.
34. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. *Kidney Int*. 2004;65(4):1366-1374
35. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. *JAMA*. 2003;289(5):553-558.
36. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. *J Am Coll Cardiol*. 2002;40(8):1383-1388
37. Adabag AS, Ishani A, Koneswaran S, et al. UtilityofN-acetylcysteinetopreventacutekidneyinjuryaftercardiacsurgery: arandomizedcontrolledtrial. *Am Heart J* 2008;155:1143–1149
38. Staniloae CS, Doucet S, Sharma SK et al. N-Acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: results from the cardiac angiography in renally impaired patients study. *J Interv Cardiol* 2009; 22: 261–265
39. Wesner AR, Brackbill ML, Stysma CS. EffectofpreoperativeN-Acetylcysteineonpostoperativeblood loss paraemetres in cardiac surgery patients. *Int J Vasc Med* 2011;2011:859020.
40. Burns KE, Chu MW, Novick RJ, et al. PerioperativeN-acetylcysteinetoprevent renal dysfunction in high-risk patients undergoing CABG surgery: a randomized controlled trial. *JAMA* 2005; 294:342–50
41. Webb JG, Pate GE, Humpries KH, et al. ArandomizedcontrolledtrialofintravenousN-acetylcysteineforthe preventionofcontrast-induced nephropathy after cardiac catheterization: lack of effect. *Am Heart J* 2004;148:422-429.

3/1/2014